• Font Size:
  • A
  • A
 questions in your Checklist | Register
IMPORTANT SAFETY INFORMATION

BETASERON® (interferon beta-1b) should be used with caution in patients with depression. Injection-site necrosis has been reported in 4% of patients in controlled trials. Patients should be advised of the importance of rotating injection sites...continue reading below

Track Injections on my mobile device

myBETAapp™ Personal Injection Reminder & Tracker

Simply sign up for BETAPLUS® and download our mobile application, myBETAapp™, to your smartphone. It lets you schedule, track and record BETASERON® (interferon beta-1b) injections whenever and wherever it's convenient for you.

myBETAapp™ lets you:

  • See today's injection plan at a glance
  • See when and where your next injection is scheduled
  • View a monthly calendar of your injection schedule
  • See missed as well as scheduled injections
  • Customize which injection sites to include in your rotation schedule
  • Decide when and how to display a reminder alert for your next injection*
  • E-mail your BETASERON injection history to yourself and your healthcare team†
  • Get easy access to the BETAPLUS patient support program online or by phone†

Get BETA Nurse support, plus tools and savings with BETAPLUS®

JOIN NOW

Please note that this app is not intended to offer or replace professional medical advice. Speak to your nurse or doctor if you have any health concerns.

Reminder alerts require an Internet connection (Wi-Fi for iPod/iPod touch, Edge/3G/4G/Wi-Fi for smartphones).

†Additional features require Internet, e-mail and/or phone service enabled on your device.

myBETAapp is available for use on devices with the following operating systems (OS): Apple iOS 3.1.3 or later, Google Android™ 2.1 or later, HP webOS 1.4.5 or later, RIM BlackBerry® OS 6.0 or later, also requires touch screen, 1 GHz CPU, 512 MB RAM.

*Apple®, iPhone® and iPod touch® are trademarks of Apple Inc. Android™ is a trademark of Google Inc. Use of this trademark is subject to Google Permissions. The Trademark BlackBerry® is owned by Research In Motion Limited and is registered in the United States and may be pending or registered in other countries. Bayer HealthCare Pharmaceuticals is not endorsed, sponsored, affiliated with or otherwise authorized by Research In Motion Limited. Palm® and Pre™ are trademarks of Palm, Inc.

INDICATIONS AND USAGE

BETASERON® (interferon beta-1b) is indicated for the treatment of relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations. Patients with multiple sclerosis in whom efficacy has been demonstrated include patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis.

IMPORTANT SAFETY INFORMATION

  • BETASERON should be used with caution in patients with depression.
  • Injection-site necrosis has been reported in 4% of patients in controlled trials. Patients should be advised of the importance of rotating injection sites.
  • Severe hepatic injury, including cases of hepatic failure, has been reported. Patients should be monitored for liver enzyme elevations while taking BETASERON.
  • BETASERON should be used with caution in patients with seizure disorders or cardiac disease.
  • Female patients should be warned about the potential risk to pregnancy.
  • Cases of anaphylaxis have been reported rarely.
  • The most commonly reported adverse reactions are lymphopenia (low numbers of a certain kind of white blood cell), Injection-site reaction, asthenia (general weakness), flu-like symptom complex (flu syndrome and/or a combination of at least two Adverse Events from fever, chills, muscle aches, tiredness and sweating), headache and pain. Gradual dose titration and use of analgesics during treatment initiation may help reduce flu-like symptoms.

See "Warnings," "Precautions," and "Adverse Reactions" sections of full Prescribing Information.

For important risk and use information, please see the full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.